The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Abstract
New blood vessel formation (angiogenesis) is a fundamental event in the process of tumor growth and metastatic dissemination. Hence, the molecular basis of tumor angiogenesis has been of keen interest in the field of cancer research. The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with overlapping and distinct ligand-receptor binding specificities, cell-type expression, and function. Activation of the VEGF-receptor pathway triggers a network of signaling processes that promote endothelial cell growth, migration, and survival from pre-existing vasculature. In addition, VEGF mediates vessel permeability, and has been associated with malignant effusions. More recently, an important role for VEGF has emerged in mobilization of endothelial progenitor cells from the bone marrow to distant sites of neovascularization. The well-established role of VEGF in promoting tumor angiogenesis and the pathogenesis of human cancers has led to the rational design and development of agents that selectively target this pathway. Studies with various anti-VEGF/VEGF-receptor therapies have shown that these agents can potently inhibit angiogenesis and tumor growth in preclinical models. Recently, an anti-VEGF antibody (bevacizumab), when used in combination with chemotherapy, was shown to significantly improve survival and response rates in patients with metastatic colorectal cancer and thus, validate VEGF pathway inhibitors as an important new treatment modality in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–219 of 219
Joo, Y., Rew, J., Seo, Y., Choi, S.-K., Kim, Y., Park, C.-S., & Kim, S.-J. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200307000-00009 · Cited by 91
Manders, P., Beex, L. V. A. M., Tjan‐Heijnen, V. C. G., Geurts-Moespot, J., van Tienoven, T., Foekens, J. A., & Sweep, F. C. G. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600555 · Cited by 90
Breast cancer during pregnancy.
Ellis, L. M., Liu, W., Fan, F., Reinmuth, N., Shaheen, R. M., Jung, Y. D., & Ahmad, S. (2001) · PubMed · Cited by 87
Self-citationEbos, J. M. L., Tran, J., Master, Z., Dumont, D., Melo, J. V., Buchdunger, E., & Kerbel, R. S. (2002) · PubMed · Cited by 80
Guo, P., Fang, Q., Tao, H.-Q., Schafer, C. A., Fenton, B. M., Ding, I., Hu, B., & Cheng, S. (2003) · PubMed · Cited by 78
Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy
Curé, H., Amat, S., Penault-Llorca, F. M., Bouëdec, G. L., Ferrière, J.-P., Mouret‐Reynier, M., Kwiatkowski, F., Feillel, V., Dauplat, J., & Chollet, P. J. M. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020274709327 · Cited by 74
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Ras regulation of vascular endothelial growth factor and angiogenesis
Rak, J. W., & Kerbel, R. S. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)33062-8 · Cited by 58
Yoshiji, H., Kuriyama, S., Hicklin, D. J., Huber, J., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., & Fukui, H. (2001) · Hepatology · doi:10.1053/jhep.2001.23312 · Cited by 56
Self-citationWild, R., Dings, R. P. M., Subramanian, I. V., & Ramakrishnan, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20100 · Cited by 55
Ikeda, N., Nakajima, Y., Sho, M., Adachi, M., Huang, C., Iki, K., Kanehiro, H., Hisanaga, M., Nakano, H., & Miyake, M. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<488::aid-cncr1347>3.0.co;2-f · Cited by 54
Fleming, R., Ellis, L. M., Parikh, N. U., Liu, W., Staley, C. A., & Gallick, G. E. (1997) · Surgery · doi:10.1016/s0039-6060(97)90044-1 · Cited by 51
Self-citationKlohs, W. D., & Hamby, J. M. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00033-6 · Cited by 51
Zhu, Z., Lu, D., Kotanides, H., Santiago, A., Jimenez, X., Simcox, T., Hicklin, D. J., Böhlen, P., & Witte, L. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00324-3 · Cited by 50
Self-citationEllis, L. M., & Hoff, P. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.971 · Cited by 48
Self-citationDunk, C., & Ahmed, A. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63965-x · Cited by 40
Chen, W. S., Kitson, R. P., & Goldfarb, R. H. (2002) · PubMed · Cited by 31
KOTSUJI, T., Imakado, S., Kawachi, Y., & Otsuka, F. (2002) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2002.tb00208.x · Cited by 19
Fujisawa, T., Watanabe, J., Kamata, Y., Hamano, M., Hata, H., & Kuramoto, H. (2003) · Experimental and Molecular Pathology · doi:10.1016/s0014-4800(03)00020-0 · Cited by 17
Cited by
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., Pogue, B. W., & Hasan, T. (2010) · Chemical Reviews · doi:10.1021/cr900300p · Cited by 2,324
Tumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,134
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Self-citation
Metadata
- Authors
- Hicklin, D. J., & Ellis, L. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-10
- Volume
- 23
- Issue
- 5
- Pages
- 1011-1027
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166573361
- Cited by
- 3,007
- References
- 219
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.